Sinocelltech Group (SHSE:688520) Growth Rank : 0 (As of Jun. 09, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Sinocelltech Group Growth Rank?

Sinocelltech Group has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Sinocelltech Group Growth Rank Related Terms

Thank you for viewing the detailed overview of Sinocelltech Group's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinocelltech Group (SHSE:688520) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinocelltech Group Ltd (SHSE:688520) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kechuang Seventh Street, Beijing Economic and Technological Development Zone, Room 307, Building 5, Courtyard 31, Beijing, CHN, 100176

Website

http://www.sinocelltech.com

Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.

Executives

Xie Liang Zhi

Director

Sinocelltech Group (SHSE:688520) Headlines

No Headlines